Dr. John Cush RheumNow
3 weeks 3 days ago
DERM on RheumNow (June 2026)
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy and side effects. https://t.co/vy4BAx8Lnq
Dr. John Cush RheumNow
3 weeks 3 days ago
ICYMI: Glucocorticoid Injections in Knee Osteoarthritis
A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to https://t.co/QhW7CMx72x
Dr. John Cush RheumNow
3 weeks 4 days ago
ICYMI: EGPA Review
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
https://t.co/rFGoYBMwCP https://t.co/U0HRR7XeVT
Dr. John Cush RheumNow
3 weeks 4 days ago
ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management
EULAR has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous https://t.co/6WAZB1dOpI
Dr. John Cush RheumNow
3 weeks 4 days ago
ICYMI: B Cells at the Brink in Sjögren Disease
The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder. https://t.co/OBFqHYof5m
EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.
A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates
Dr. John Cush RheumNow
3 weeks 4 days ago
RT @minidey #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026
Dr. John Cush RheumNow
3 weeks 4 days ago
RT @aurelierheumo Failure to achieve early remission RA asso w/ non-inflammatory pain
NORD-STAR 526 early RA pts)
no remission at 24 wks increased risk of 48wk
• unacceptable pain (OR ~6)
• refractory pain (OR ~6)
• fibromyalgic RA (OR ~16)
Signal strongest w/ very early
Dr. John Cush RheumNow
3 weeks 4 days ago
EULAR26: Reports on Systemic Sclerosis
https://t.co/knZZlMYlen https://t.co/0wul0yaw4m
Dr. John Cush RheumNow
3 weeks 5 days ago
Generic Tofacitinib (6.26.2026)
Dr. Jack Cush reviews the news and journal articles from https://t.co/V10S4oVFsv. Updates on tofacitinib, CAR-T therapy and AI.
https://t.co/DNWh7taaN6 https://t.co/4r5fuooqWn
RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed the survey.
Dr. John Cush RheumNow
3 weeks 5 days ago
EULAR26: Updates in SLE and APS
Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.
https://t.co/DP7gPvlGhU https://t.co/imN6Xb7QGT
At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD).
Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.
